Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.51 |
| ▸ | GRIN2D | O15399 | 4/20 | 0.49 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.49 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.49 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.49 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4024456 | 0.90 | KMT2A (0.59) | KMT2AMEN1BCHEKDM4CGRIN2D | |
| SCHEMBL4025105 | 0.89 | KDM4C (0.53) | KMT2AMEN1BCHEKDM4CGRIN2D | |
| SCHEMBL4025053 | 0.87 | KMT2A (0.65) | KMT2AMEN1BCHEKDM4CGRIN2D | |
| SCHEMBL4024598 | 0.87 | KMT2A (0.55) | KMT2AMEN1BCHEKDM4CGRIN2D | |
| SCHEMBL5742442 | 0.87 | KMT2A (0.65) | KMT2AMEN1BCHEKDM4CGRIN2D | |
| SCHEMBL6181835 | 0.85 | KMT2A (0.53) | KMT2AMEN1BCHEKDM4CGRIN2D | |
| Hydrochloric Acid SCHEMBL11616569 | 0.85 | KMT2A (0.48) | KMT2AMEN1BCHEKDM4CGRIN2D | |
| SCHEMBL4025943 | 0.84 | KMT2A (0.52) | KMT2AMEN1BCHEKDM4CGRIN2D | |
| SCHEMBL6374574 | 0.84 | KMT2A (0.64) | KMT2AMEN1BCHEKDM4CTSHR | |
| SCHEMBL4026551 | 0.83 | KDM4C (0.52) | KMT2AMEN1BCHEKDM4CGRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1611104-B1 | TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-07-01 | — | — | EP | disclosed |
| EP-1611104-B1 | TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-07-01 | — | — | EP | disclosed |
| US-20060178515-A1 | Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists | ACTELION PHARMACEUTICALS, LTD. (CH) | 2006-08-10 | — | — | US | disclosed |
| EP-1611104-A1 | TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004085403-A1 | TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004085403-A1 | TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178515-A1 | Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists | HCRTR2, HCRTR1, OXTR | KMT2A 1035/4885MEN1 1135/4885BCHE 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.